## Gene Summary
MYOCD, short for Myocardin, is a coactivator of serum response factor (SRF), playing a crucial role in the transcriptional regulation of cardiac and smooth muscle cell development. MYOCD is predominantly expressed in cardiac and smooth muscle tissues. The myocardin protein is critical in the control of cardiovascular development, by promoting the expression of genes related to muscle contraction and structure. It acts by interacting with SRF, leading to the activation of muscle-specific target genes.

## Gene Drugs, Diseases, Phenotypes, and Pathways
MYOCD's function ties it to various cardiovascular diseases due to its key role in muscle gene regulation and cardiovascular formation. It has been implicated in conditions such as cardiac hypertrophy and congenital heart defects. The gene participates in pathways including the regulation of actin cytoskeleton and pathways in cancer, focusing particularly on its role in maintaining smooth muscle phenotype and pathological cardiac remodeling. Altered MYOCD expression has been associated with diseases involving smooth muscle dysfunction, including vascular diseases.

## Pharmacogenetics
Pharmacogenetic studies on MYOCD are relatively limited compared to other genes more directly involved in drug metabolism. However, its critical role in cardiac and smooth muscle function hints at potential implications in pharmacogenetic contexts, particularly in response to drugs affecting cardiovascular system or muscle function. While specific drug associations are not well-documented, understanding MYOCD's activity and genetic variants could influence the strategies for treating cardiovascular diseases, potentially guiding personalized therapies in cardiac hypertrophy or myocardial infarction where muscle remodelling plays a crucial role. Further research into MYOCD's pharmacogenetics could open new avenues for targeted cardiovascular therapies.